Isocitrate dehydrogenase mutations in defining the biology of and supporting clinical decision making in glioblastoma.

Somatic mutations in isoforms of IDH genes represent important biomarkers that correlate with biochemical, biological and phenotypic features of glioblastoma, and may also facilitate the development of new therapeutic strategies complementing the currently available approved protocols.